\-\ Texto\\:\\ \ \(0\)\
\-\ no\\ specific\\ findings\\ noted\\.\\ possibly\\ enlarged\\ and\\ irregular\\ uterus\\ on\\ bimanual\\ exam\\.\ \(0\)\
\-\ depending\\ on\\ the\\ patient\\'s\\ symptoms\\,\\ surgical\\ options\\ may\\ be\\ discussed\\.\ \(0\)\
\-\ numerous\\ areas\\ of\\ discrete\\ low\\ signal\\ intensity\\ in\\ the\\ muscle\\ of\\ the\\ uterus\\ and\\ below\\ the\\ serosa\\.\\ uterus\\ is\\ irregularly\\ enlarged\\.\ \(0\)\
\-\ uterine\\ leiomyoma\ \(5\)\
\-\ adenomyosis\ \(10\)\
\-\ leiomyosarcoma\ \(24\)\
\-\ endometrial\\ polyps\ \(2\)\
\-\ endometrial\\ cancer\ \(5\)\
\-\ patient\\ referred\\ by\\ ob\\-gyn\\ for\\ pelvic\\ mri\\.\\ no\\ symptoms\\ noted\\.\ \(0\)\
\-\ lesions\\/condition\\:\\ uterine\\ leiomyoma\\ \ \(0\)\
\-\ cell\\ of\\ origin\\:\\ smooth\\ muscle\\ cells\\ of\\ uterus\\ \ \(0\)\
\-\ synonyms\\:\\ fibroids\\ \ \(0\)\
\-\ associations\\/predisposing\\ factors\\:\\ increase\\ estrogen\\ states\\,\\ pregnancy\\,\\ african\\ american\\,\\ obesity\\,\\ perimenopausal\\ \ \(0\)\
\-\ common\\ locations\\:\\ uterus\\;\\ submucosal\\,\\ intramural\\,\\ subserosal\\ \ \(0\)\
\-\ demographics\\:\\ about\\ 25\\%\\ of\\ american\\ women\\ and\\ about\\ 40\\%\\ of\\ african\\ american\\ women\\ by\\ age\\ 40\\.\\ \ \(0\)\
\-\ gross\\ morphology\\:\\ smooth\\ muscle\\ tissue\\ \ \(0\)\
\-\ histology\\:\\ smooth\\ muscle\\ tissue\\ with\\ a\\ pseudocapsule\\ \ \(0\)\
\-\ radiology\\:\\ ultrasound\\ shows\\ areas\\ of\\ hyperechogenicity\\ and\\ an\\ enlarged\\ uterus\\.\\ mri\\ shows\\ discrete\\ areas\\ of\\ low\\ signal\\ intensity\\ and\\ an\\ irregularly\\ enlarged\\ uterus\\.\\ \ \(0\)\
\-\ treatment\\:\\ usually\\ expectant\\ management\\.\\ if\\ symptomatic\\,\\ treated\\ with\\ medications\\ to\\ decrease\\ estrogen\\ \\(provera\\,\\ danazol\\,\\ gnrh\\ agonists\\)\\,\\ uterine\\ artery\\ embolization\\,\\ myomectomy\\,\\ endometrial\\ ablation\\,\\ or\\ hysterectomy\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ uterus\\:\\ 0\\.1368746930499571\ \(0\)\
\-\ \\-endometrial\\:\\ 0\\.08558755751423784\ \(0\)\
\-\ uterine\\:\\ 0\\.06385487803577453\ \(0\)\
\-\ estrogen\\:\\ 0\\.06146225023474269\ \(0\)\
\-\ muscle\\:\\ 0\\.059598354047113486\ \(0\)\
\-\ american\\:\\ 0\\.059280382945678375\ \(0\)\
\-\ enlarged\\:\\ 0\\.05661400136667973\ \(0\)\
\-\ \\:\\:\\ 0\\.05486770951410995\ \(0\)\
\-\ smooth\\:\\ 0\\.0544710379912525\ \(0\)\
\-\ irregularly\\:\\ 0\\.053955552290728306\ \(0\)\
\-\ leiomyoma\\:\\ 0\\.048847852330565406\ \(0\)\
\-\ discrete\\:\\ 0\\.047802894425785156\ \(0\)\
\-\ african\\:\\ 0\\.04328941356579521\ \(0\)\
\-\ \\-leiomyosarcoma\\:\\ 0\\.04279377875711892\ \(0\)\
\-\ associations\\/predisposing\\:\\ 0\\.04279377875711892\ \(0\)\
\-\ provera\\:\\ 0\\.04279377875711892\ \(0\)\
\-\ danazol\\:\\ 0\\.04279377875711892\ \(0\)\
\-\ myomectomy\\:\\ 0\\.04279377875711892\ \(0\)\
\-\ areas\\:\\ 0\\.041873987930767964\ \(0\)\
\-\ women\\:\\ 0\\.04031144980441195\ \(0\)\
\-\ \\-adenomyosis\\:\\ 0\\.03942898661847841\ \(0\)\
\-\ lesions\\/condition\\:\\ 0\\.03942898661847841\ \(0\)\
\-\ perimenopausal\\:\\ 0\\.03942898661847841\ \(0\)\
\-\ gnrh\\:\\ 0\\.03942898661847841\ \(0\)\
\-\ hyperechogenicity\\:\\ 0\\.03746070939465237\ \(0\)\
\-\ serosa\\:\\ 0\\.0360641944798379\ \(0\)\
\-\ ob\\-gyn\\:\\ 0\\.0360641944798379\ \(0\)\
\-\ 40\\.\\:\\ 0\\.03498097335695338\ \(0\)\
\-\ pseudocapsule\\:\\ 0\\.03498097335695338\ \(0\)\
\-\ agonists\\:\\ 0\\.03498097335695338\ \(0\)\
\-\ synonyms\\:\\ 0\\.034095917256011854\ \(0\)\
\-\ subserosal\\:\\ 0\\.034095917256011854\ \(0\)\
\-\ expectant\\:\\ 0\\.034095917256011854\ \(0\)\
\-\ about\\:\\ 0\\.03198114083596361\ \(0\)\
\-\ intensity\\:\\ 0\\.029987093945430105\ \(0\)\
\-\ demographics\\:\\ 0\\.02998282084636524\ \(0\)\
\-\ bimanual\\:\\ 0\\.029647903994486833\ \(0\)\
\-\ hysterectomy\\:\\ 0\\.02757293304872499\ \(0\)\
\-\ fibroids\\:\\ 0\\.026618028707724724\ \(0\)\
\-\ intramural\\:\\ 0\\.026447682495048655\ \(0\)\
\-\ submucosal\\:\\ 0\\.02628311185584632\ \(0\)\
\-\ obesity\\:\\ 0\\.025969818063916364\ \(0\)\
\-\ ablation\\:\\ 0\\.025969818063916364\ \(0\)\
\-\ polyps\\:\\ 0\\.0251355935157287\ \(0\)\
\-\ morphology\\:\\ 0\\.02476672988962228\ \(0\)\
\-\ histology\\:\\ 0\\.024649751483898686\ \(0\)\
\-\ locations\\:\\ 0\\.02420814091008448\ \(0\)\
\-\ endometrial\\:\\ 0\\.023520517040846487\ \(0\)\
\-\ low\\:\\ 0\\.02306959274627572\ \(0\)\
\-\ shows\\:\\ 0\\.022809453395426005\ \(0\)\
\-\ discussed\\:\\ 0\\.022681474260072648\ \(0\)\
\-\ signal\\:\\ 0\\.02187450806090076\ \(0\)\
\-\ depending\\:\\ 0\\.021582866851939206\ \(0\)\
\-\ possibly\\:\\ 0\\.021227510521729036\ \(0\)\
\-\ symptoms\\:\\ 0\\.020676286183477076\ \(0\)\
\-\ options\\:\\ 0\\.020155724902205976\ \(0\)\
\-\ gross\\:\\ 0\\.019760127648559455\ \(0\)\
\-\ noted\\:\\ 0\\.01966428338303489\ \(0\)\
\-\ tissue\\:\\ 0\\.01966428338303489\ \(0\)\
\-\ states\\:\\ 0\\.019513242128008527\ \(0\)\
\-\ \\%\\:\\ 0\\.01935263139170881\ \(0\)\
\-\ embolization\\:\\ 0\\.019316682121432137\ \(0\)\
\-\ mri\\:\\ 0\\.019060930630239028\ \(0\)\
\-\ origin\\:\\ 0\\.019017857398133914\ \(0\)\
\-\ decrease\\:\\ 0\\.01898176526955373\ \(0\)\
\-\ factors\\:\\ 0\\.018634877094883123\ \(0\)\
\-\ numerous\\:\\ 0\\.01860151360319496\ \(0\)\
\-\ medications\\:\\ 0\\.01850277727194679\ \(0\)\
\-\ \\,\\:\\ 0\\.018397771442922442\ \(0\)\
\-\ below\\:\\ 0\\.018007635679931636\ \(0\)\
\-\ pregnancy\\:\\ 0\\.017834246929436106\ \(0\)\
\-\ radiology\\:\\ 0\\.017531610373250982\ \(0\)\
\-\ 40\\:\\ 0\\.017452245625670743\ \(0\)\
\-\ increase\\:\\ 0\\.017400047607339375\ \(0\)\
\-\ specific\\:\\ 0\\.017147158714701502\ \(0\)\
\-\ pelvic\\:\\ 0\\.01702548896390919\ \(0\)\
\-\ 25\\:\\ 0\\.016768088632315888\ \(0\)\
\-\ cells\\:\\ 0\\.016633236379368917\ \(0\)\
\-\ irregular\\:\\ 0\\.01654537209954553\ \(0\)\
\-\ symptomatic\\:\\ 0\\.01648050206162239\ \(0\)\
\-\ referred\\:\\ 0\\.015653065259493403\ \(0\)\
\-\ management\\:\\ 0\\.015653065259493403\ \(0\)\
\-\ by\\:\\ 0\\.013814280614027908\ \(0\)\
\-\ cancer\\:\\ 0\\.013636724584294976\ \(0\)\
\-\ age\\:\\ 0\\.012625778279341292\ \(0\)\
\-\ usually\\:\\ 0\\.012596739096440577\ \(0\)\
\-\ treated\\:\\ 0\\.012416751631475044\ \(0\)\
\-\ artery\\:\\ 0\\.012352087340331061\ \(0\)\
\-\ ultrasound\\:\\ 0\\.012306420315564578\ \(0\)\
\-\ an\\:\\ 0\\.011472474410531357\ \(0\)\
\-\ if\\:\\ 0\\.011256036086313764\ \(0\)\
\-\ cell\\:\\ 0\\.011205051997968379\ \(0\)\
\-\ common\\:\\ 0\\.010855666077458238\ \(0\)\
\-\ \\;\\:\\ 0\\.009832141691517445\ \(0\)\
\-\ \\'s\\:\\ 0\\.00914585737071381\ \(0\)\
\-\ exam\\:\\ 0\\.009112786116259894\ \(0\)\
\-\ may\\:\\ 0\\.009098681402418075\ \(0\)\
\-\ findings\\:\\ 0\\.008829305513543493\ \(0\)\
\-\ surgical\\:\\ 0\\.008719523156560454\ \(0\)\
\-\ treatment\\:\\ 0\\.008396198833014014\ \(0\)\
\-\ no\\:\\ 0\\.008353826705862155\ \(0\)\
\-\ patient\\:\\ 0\\.008316426513751338\ \(0\)\
\-\ on\\:\\ 0\\.007028068081217748\ \(0\)\
\-\ be\\:\\ 0\\.006396877297786063\ \(0\)\
\-\ or\\:\\ 0\\.00486176091729955\ \(0\)\
\-\ of\\:\\ 0\\.004524419448465569\ \(0\)\
\-\ and\\:\\ 0\\.004369150624568409\ \(0\)\
\-\ for\\:\\ 0\\.003539359944867549\ \(0\)\
\-\ \\(\\:\\ 0\\.003506610321572138\ \(0\)\
\-\ \\)\\:\\ 0\\.0034637752044335197\ \(0\)\
\-\ is\\:\\ 0\\.0027295668853627455\ \(0\)\
\-\ the\\:\\ 0\\.002684452130167491\ \(0\)\
\-\ to\\:\\ 0\\.0020731461574902245\ \(0\)\
\-\ in\\:\\ 0\\.0020456176220400722\ \(0\)\
\-\ a\\:\\ 0\\.0019252417564009769\ \(0\)\
\-\ \\.\\:\\ 0\\.0018956062964602379\ \(0\)\
\-\ with\\:\\ 0\\.0011359628746591235\ \(0\)\
